Biosimilars undergo rigorous comparison with their reference product to ensure pharmacokinetic (PK) and pharmacodynamic similarities, immunogenicity, and efficacy, but any data limitations must be ...
Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer The following represents disclosure information provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results